Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Rheumatoid Arthritis HELP
Based on 27,390 articles since 2006
||||

These are the 27390 published articles about Arthritis, Rheumatoid that originated from Worldwide during 2006-2015.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline EULAR recommendations for patient education for people with inflammatory arthritis. 2015

Zangi, Heidi A / Ndosi, Mwidimi / Adams, Jo / Andersen, Lena / Bode, Christina / Boström, Carina / van Eijk-Hustings, Yvonne / Gossec, Laure / Korandová, Jana / Mendes, Gabriel / Niedermann, Karin / Primdahl, Jette / Stoffer, Michaela / Voshaar, Marieke / van Tubergen, Astrid / Anonymous3100808. ·Department of Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. · School of Healthcare, University of Leeds, Leeds, UK and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. · Centre for Innovation and Leadership in Health Faculty of Health Sciences University of Southampton Highfield, Southampton, UK. · Nyborg, Denmark. · Department of Psychology, University of Twente, Health & Technology, Enschede, The Netherlands. · Division of physiotherapy, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. · Department of Patient & Care/ Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands CAPHRI, School for Public Health and Primary Care, University of Maastricht, Maastricht, The Netherlands. · Sorbonne Universités, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France Department of rheumatology, AP-HP, Pitié Salpêtrière Hospital, Paris, France. · Institute of Rheumatology, Prague, Czech Republic. · Department of National Team, Portuguese Cycling Federation, Lisbon, Portugal. · Institute of Physiotherapy, School of Health Professions, Zurich University of Applied Sciences, Winterthur, Switzerland. · Institute for Regional Health Research, University of Southern Denmark, Odense, Denmark Hospital of Southern Jutland, Aabenraa, Denmark King Christian X's Hospital for Rheumatic Diseases, Graasten, Denmark. · Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria. · Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands. · Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands. · ·Ann Rheum Dis · Pubmed #25735643.

ABSTRACT: OBJECTIVES: The task force aimed to: (1) develop evidence-based recommendations for patient education (PE) for people with inflammatory arthritis, (2) identify the need for further research on PE and (3) determine health professionals' educational needs in order to provide evidence-based PE. METHODS: A multidisciplinary task force, representing 10 European countries, formulated a definition for PE and 10 research questions that guided a systematic literature review (SLR). The results from the SLR were discussed and used as a basis for developing the recommendations, a research agenda and an educational agenda. The recommendations were categorised according to level and strength of evidence graded from A (highest) to D (lowest). Task force members rated their agreement with each recommendation from 0 (total disagreement) to 10 (total agreement). RESULTS: Based on the SLR and expert opinions, eight recommendations were developed, four with strength A evidence. The recommendations addressed when and by whom PE should be offered, modes and methods of delivery, theoretical framework, outcomes and evaluation. A high level of agreement was achieved for all recommendations (mean range 9.4-9.8). The task force proposed a research agenda and an educational agenda. CONCLUSIONS: The eight evidence-based and expert opinion-based recommendations for PE for people with inflammatory arthritis are intended to provide a core framework for the delivery of PE and training for health professionals in delivering PE across Europe.

2 Guideline Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. 2014

Gaujoux-Viala, Cécile / Gossec, Laure / Cantagrel, Alain / Dougados, Maxime / Fautrel, Bruno / Mariette, Xavier / Nataf, Henri / Saraux, Alain / Trope, Sonia / Combe, Bernard / Anonymous4130786. ·Department of Rheumatology, Nîmes University Hospital, EA 2415, Montpellier I University, 30029 Nîmes, France. Electronic address: cecile.gaujoux.viala@chu-nimes.fr. · Sorbonne Universities, UPMC Univ Paris 06, GRC 08, institut Pierre Louis d'épidémiologie et de santé publique; AP-HP, Department of Rheumatology, CHU Pitié-Salpetrière, 75013 Paris, France. · Department of Rheumatology, Purpan Hospital, CHRU de Toulouse, Paul Sabatier Toulouse III University, UMR Inserm 1043-CNRS 5282, 31059 Toulouse, France. · Paris Descartes University - Department of Rheumatology -Cochin Hospital, Assistance Publique - Hôpitaux de Paris - INSERM (U1153): épidémiologie clinique et biostatistiques, PRES Sorbonne Paris-Cité, 75014 Paris, France. · Department of Rheumatology, Paris-Sud Universities Hospital, AP-HP, Inserm U 1012, Paris Sud University, 92276 Le Kremlin Bicêtre, France. · Cabinet de rhumatologie, 78200 Mantes la Jolie, Yvelines, France. · Department of rheumatology, CHU de la Cavale Blanche, boulevard Tanguy-Prigent, 29609 Brest, France; EA 2216, Bretagne Occidentale University, 29200 Brest, France. · Association nationale de défense contre l'arthrite rhumatoïde (ANDAR), 75014 Paris, France. · Department of rheumatology, Lapeyronie Hospital, CHRU de Montpellier, Montpellier I University, UMR 5535, 34295 Montpellier, France. · ·Joint Bone Spine · Pubmed #24986683.

ABSTRACT: INTRODUCTION: This article reports the latest recommendations of the French Society for Rheumatology (SFR) regarding the management of rheumatoid arthritis (RA). METHODS: New recommendations were developed by hospital- and community-based rheumatologists having extensive experience with RA and a patient self-help organization representative. They rest on the recently issued EULAR recommendations and a literature review. RESULTS: Points emphasized in the 15 recommendations include the need to share treatment decisions between the rheumatologist and the patient, the acquisition by patients of self-management skills, remission or minimal disease activity as the treatment target, the need for initiating disease-modifying drugs as early as possible, and the usefulness of regular disease activity assessments to allow rapid treatment adjustments if needed (i.e., tight disease control). First-line methotrexate monotherapy is recommended, with concomitant short-term glucocorticoid therapy if indicated by the risk/benefit ratio. Patients who fail this approach (no response after 3 months or target not achieved after 6 months) can be considered for another synthetic disease-modifying antirheumatic drug (DMARD: leflunomide or sulfasalazine), combined synthetic DMARD therapy, or methotrexate plus a biologic, depending on the prognostic factors and patient characteristics. If the first biologic fails, switching to a second biologic is recommended. In the event of a sustained remission, cautious dosage reduction of the biological and/after synthetic DMARDs is in order. CONCLUSION: These recommendations are designed to improve the management of patients with RA.

3 Guideline [Recommendations for use of abatacept in patients with rheumatoid arthritis]. 2014

Gaubitz, M / Krüger, K / Haas, J-P / Anonymous1710798. ·Akademie für Manuelle Therapie an der WWU Münster, Münster, Deutschland. · ·Z Rheumatol · Pubmed #24903655.

ABSTRACT: -- No abstract --

4 Guideline The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. 2014

Malaviya, Anshuman P / Ledingham, Jo / Bloxham, Jill / Bosworth, Aisla / Buch, Maya / Choy, Ernest / Cope, Andrew / Isaacs, John / Marshall, David / Wright, Gary / Ostör, Andrew J K / Anonymous4800784 / Anonymous4810784. ·Department of Rheumatology, Broomfield Hospital, Chelmsford, Essex, Department of Rheumatology, Queen Alexandra Hospital, Portsmouth, Department of Rheumatology, Addenbrookes Hospital, Cambridge, National Rheumatoid Arthritis Society, Maidenhead, Berkshire, Academic Section of Musculoskeletal Disease, University of Leeds, Leeds, Department of Medicine, Cardiff University School of Medicine, Cardiff, Department of Rheumatology, Kings College London, London, Musculoskeletal Research Group, Newcastle University, Newcastle, Department of Rheumatology, Inverclyde Royal Hospital, Glasgow, Department of Rheumatology, Royal Victoria Hospital, Belfast and Department of Rheumatology, Addenbrookes Hospital, Cambridge, UK. a.malaviya@nhs.net. · Department of Rheumatology, Broomfield Hospital, Chelmsford, Essex, Department of Rheumatology, Queen Alexandra Hospital, Portsmouth, Department of Rheumatology, Addenbrookes Hospital, Cambridge, National Rheumatoid Arthritis Society, Maidenhead, Berkshire, Academic Section of Musculoskeletal Disease, University of Leeds, Leeds, Department of Medicine, Cardiff University School of Medicine, Cardiff, Department of Rheumatology, Kings College London, London, Musculoskeletal Research Group, Newcastle University, Newcastle, Department of Rheumatology, Inverclyde Royal Hospital, Glasgow, Department of Rheumatology, Royal Victoria Hospital, Belfast and Department of Rheumatology, Addenbrookes Hospital, Cambridge, UK. · ·Rheumatology (Oxford) · Pubmed #24821853.

ABSTRACT: -- No abstract --

5 Guideline [Evidence-based recommendations for the management of undifferentiated peripheral inflammatory arthritis (UPIA). The German perspective on the international 3e initiative]. 2014

Tarner, I H / Albrecht, K / Fleck, M / Gromnica-Ihle, E / Keyßer, G / Köhler, L / Kötter, I / Krüger, K / Kuipers, J / Nüßlein, H / Rubbert-Roth, A / Wollenhaupt, J / Schneider, M / Manger, B / Müller-Ladner, U / Anonymous160781. ·Abt. für Rheumatologie, Klinische Immunologie, Osteologie und Physikalische Medizin,Kerckhoff-Klinik, Lehrstuhl für Innere Medizin mit Schwerpunkt Rheumatologie, Justus-Liebig-Universität Gießen, Benekestr. 2-8, 61231, Bad Nauheim, Deutschland. · ·Z Rheumatol · Pubmed #24590079.

ABSTRACT: INTRODUCTION: Peripheral arthritis is the most common presenting complaint in clinical rheumatology. Unequivocal identification of the underlying entity can be difficult, particularly at an early stage. Such cases are commonly referred to as undifferentiated peripheral inflammatory arthritis (UPIA). Since evidence-based recommendations for the clinical management of UPIA are lacking, this international 3e initiative convened 697 rheumatologists from 17 countries to develop appropriate recommendations. METHODS: Based on a systematic literature research in Medline, EMBASE, Cochrane Library, and the ACR/EULAR abstracts of 2007/2008, 10 multinational recommendations were developed by 3 rounds of a Delphi process. In Germany, a national group of experts worked on 3 additional recommendations using the same method. The recommendations were discussed among the members of the 3e initiative and the degree of consensus was analyzed as well as the potential impact of the recommendations on clinical practice. RESULTS: A total of 39,756 references were identified, of which 250 were systematically reviewed for the development of 10 multinational recommendations concerning differential diagnosis, diagnostic and prognostic value of clinical assessments, laboratory tests and imaging techniques, and monitoring of UPIA. In addition, 3 national recommendations on the diagnostic and prognostic value of a response to anti-inflammatory therapy on the analysis of synovial fluid and on enthesitis were developed by the German experts based on 35 out of 5542 references. CONCLUSIONS: The article translates the 2011 published original paper of the international 3e initiative (Machado et al., Ann Rheum Dis 70:15-24, 2011) and reports the methods and results of the national vote and the additional 3 national recommendations.

6 Guideline EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. 2014

Smolen, Josef S / Landewé, Robert / Breedveld, Ferdinand C / Buch, Maya / Burmester, Gerd / Dougados, Maxime / Emery, Paul / Gaujoux-Viala, Cécile / Gossec, Laure / Nam, Jackie / Ramiro, Sofia / Winthrop, Kevin / de Wit, Maarten / Aletaha, Daniel / Betteridge, Neil / Bijlsma, Johannes W J / Boers, Maarten / Buttgereit, Frank / Combe, Bernard / Cutolo, Maurizio / Damjanov, Nemanja / Hazes, Johanna M W / Kouloumas, Marios / Kvien, Tore K / Mariette, Xavier / Pavelka, Karel / van Riel, Piet L C M / Rubbert-Roth, Andrea / Scholte-Voshaar, Marieke / Scott, David L / Sokka-Isler, Tuulikki / Wong, John B / van der Heijde, Désirée. ·Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, , Vienna, Austria. · ·Ann Rheum Dis · Pubmed #24161836.

ABSTRACT: In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and summarised by the experts in the course of a consensus finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) were determined. Fourteen recommendations were developed (instead of 15 in 2010). Some of the 2010 recommendations were deleted, and others were amended or split. The recommendations cover general aspects, such as attainment of remission or low disease activity using a treat-to-target approach, and the need for shared decision-making between rheumatologists and patients. The more specific items relate to starting DMARD therapy using a conventional sDMARD (csDMARD) strategy in combination with glucocorticoids, followed by the addition of a bDMARD or another csDMARD strategy (after stratification by presence or absence of adverse risk factors) if the treatment target is not reached within 6 months (or improvement not seen at 3 months). Tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, biosimilars), abatacept, tocilizumab and, under certain circumstances, rituximab are essentially considered to have similar efficacy and safety. If the first bDMARD strategy fails, any other bDMARD may be used. The recommendations also address tofacitinib as a targeted sDMARD (tsDMARD), which is recommended, where licensed, after use of at least one bDMARD. Biosimilars are also addressed. These recommendations are intended to inform rheumatologists, patients, national rheumatology societies and other stakeholders about EULAR's most recent consensus on the management of RA with sDMARDs, glucocorticoids and bDMARDs. They are based on evidence and expert opinion and intended to improve outcome in patients with RA.

7 Guideline German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. 2014

Albrecht, Katinka / Krüger, Klaus / Wollenhaupt, Jürgen / Alten, Rieke / Backhaus, Marina / Baerwald, Christoph / Bolten, Wolfgang / Braun, Jürgen / Burkhardt, Harald / Burmester, Gerd R / Gaubitz, Markus / Gause, Angela / Gromnica-Ihle, Erika / Kellner, Herbert / Kuipers, Jens / Krause, Andreas / Lorenz, Hans-Martin / Manger, Bernhard / Nüßlein, Hubert / Pott, Hans-Georg / Rubbert-Roth, Andrea / Schneider, Matthias / Specker, Christof / Schulze-Koops, Hendrik / Tony, Hans-Peter / Wassenberg, Siegfried / Müller-Ladner, Ulf / Anonymous4850770. ·German Society of Rheumatology, Berlin, Germany, katinka.albrecht@dgrh.de. · ·Rheumatol Int · Pubmed #23942828.

ABSTRACT: The German Society of Rheumatology approved new German guidelines for the sequential medical treatment of rheumatoid arthritis (RA) based on the European League Against Rheumatism (EULAR) recommendations for the management of RA published in 2010. An update of the EULAR systematic literature research was performed in Medline, Embase, and Cochrane databases. Meta-analyses, controlled trials, cohort studies, and registry data addressing traditional and biologic disease-modifying antirheumatic drugs, glucocorticoids, and treatment strategies published between January 2009 and August 2011 were included. Two reviewers independently evaluated and compared the additional data that had been published after the time limit set by the EULAR recommendations. A national guideline working group developed an adapted set of recommendations. The new German guidelines were accepted by vote using an informal Delphi approach. Twelve recommendations and the resulting updated treatment algorithm were developed and approved as a practical orientation for rheumatologists. These recommendations are based on a successive treatment with traditional and biologic disease-modifying drugs depending on the individual progress of the disease and distinct patient characteristics. The German guidelines have been developed on the basis of the internationally well-recognized EULAR recommendations. In addition, more recent evidence from a systematic literature research was considered. They have been developed and approved by a group of national experts aiming at guidance for rheumatologists to reach best medical practice.

8 Guideline [The proposal of the Croatian Society for Rheumatology for the treatment of adult rheumatoid arthritis patients with biologics, 2013]. 2013

Babić-Naglić, Durdica / Anić, Branimir / Čikeš, Nada / Novak, Srdan / Grazio, Simeon / Morović-Vergles, Jadranka / Kehler, Tatjana / Marasović-Krstulović, Daniela / Milanović, Sonja / Hanih, Marino / Perić, Porin / Vlak, Tonko / Potokič, Kristina / Ćurković, Božidar / Anonymous5040757. ·Klinika za reumatske bolesti i rehabilitaciju Klinicki bolnicki centar Zagreb. dnaglic@kbc-zagreb.hr · ·Reumatizam · Pubmed #24003685.

ABSTRACT: Standardized approach to the patients with rheumatoid arthritis (RA) is one of the requirements of good clinical practice. Croatian Society for Rheumatology (HRD) of Croatian Medical Association (HLZ) updated the Proposed treatment of rheumatoid arthritis (RA) with biologic agents in line with recent findings in rheumatology for the last 3 years. By complying with the agreed standards of treatment we can avoid malpractice and irrational consumption, and to the most patients provide a greater chance for a favorable outcome.

9 Guideline South African recommendations for the management of rheumatoid arthritis: an algorithm for the standard of care in 2013. 2013

Hodkinson, Bridget / Van Duuren, Elsa / Pettipher, Clive / Kalla, Asgar / Anonymous3880754. ·Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa. drbridget@gmail.com · ·S Afr Med J · Pubmed #23885741.

ABSTRACT: Updated treatment recommendations for the therapy of rheumatoid arthritis (RA) in South Africa advocate early diagnosis, prompt initiation of disease-modifying anti-rheumatic drugs (DMARDs), and an intense treatment strategy where disease activity is assessed with a composite score such as the Simplified Disease Activity Index (SDAI). Frequent assessments and escalation of therapy are necessary until low disease activity (LDA) (SDAI ≤11) or ideally remission (SDAI ≤3.3) is achieved. Synthetic DMARDs may be used as monotherapy or in combination, and can be co-prescribed with low-dose corticosteroids if necessary. Biologic DMARD therapy should be considered for patients who have failed a 6-month trial of at least 3 synthetic DMARDs. All RA patients in SA are at increased risk of tuberculosis (TB), in particular patients using anti-tumour necrosis factor (TNF) biologic therapy. These recommendations provide practical suggestions for the screening and management of TB and other comorbidities, and offer an approach to monitoring of RA patients.

10 Guideline Guidelines for the drug treatment of rheumatoid arthritis. 2013

Mota, Licia Maria Henrique da / Cruz, Bóris Afonso / Brenol, Claiton Viegas / Pereira, Ivânio Alves / Rezende-Fronza, Lucila Stange / Bertolo, Manoel Barros / Freitas, Max Vitor Carioca / Silva, Nilzio Antônio da / Louzada-Junior, Paulo / Giorgi, Rina Dalva Neubarth / Lima, Rodrigo Aires Corrêa / Bernardo, Wanderley Marques / Pinheiro, Geraldo da Rocha Castelar / Anonymous4490753. ·liciamhmota@gmail.com · ·Rev Bras Reumatol · Pubmed #23856794.

ABSTRACT: -- No abstract --

11 Guideline Guidelines for the diagnosis of rheumatoid arthritis. 2013

Mota, Licia Maria Henrique da / Cruz, Bóris Afonso / Brenola, Claiton Viegas / Pereira, Ivânio Alves / Rezende-Fronza, Lucila Stange / Bertolo, Manoel Barros / Freitas, Max Vitor Carioca / Silva, Nilzio Antônio da / Louzada-Junior, Paulo / Giorgi, Rina Dalva Neubarth / Lima, Rodrigo Aires Corrêa / Kairalla, Ronaldo Adib / Kawassaki, Alexandre de Melo / Bernardo, Wanderley Marques / Pinheiro, Geraldo da Rocha Castelar / Anonymous4460753 / Anonymous4470753 / Anonymous4480753. ·liciamhmota@gmail.com · ·Rev Bras Reumatol · Pubmed #23856793.

ABSTRACT: -- No abstract --

12 Guideline 2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis. 2013

Brenol, Claiton Viegas / da Mota, Licia Maria Henrique / Cruz, Bóris Afonso / Pileggi, Gecilmara Salviato / Pereira, Ivânio Alves / Rezende, Lucila Stange / Bertolo, Manoel Barros / Freitas, Max Victor Carioca / Silva, Nilzio Antônio da / Louzada-Junior, Paulo / Giorgi, Rina Dalva Neubarth / Lima, Rodrigo Aires Corrêa / Pinheiro, Geraldo da Rocha Castelar / Anonymous1570746. ·Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul, Brazil. cbrenol@hcpa.ufrgs.br · ·Rev Bras Reumatol · Pubmed #23588512.

ABSTRACT: OBJECTIVE: To elaborate recommendations to the vaccination of patients with rheumatoid arthritis (RA) in Brazil. METHOD: Literature review and opinion of expert members of the Brazilian Society of Rheumatology Committee of Rheumatoid Arthritis and of an invited pediatric rheumatologist. RESULTS AND CONCLUSIONS: The following 12 recommendations were established: 1) Before starting disease-modifying anti-rheumatic drugs, the vaccine card should be reviewed and updated; 2) Vaccines against seasonal influenza and against H1N1 are indicated annually for patients with RA; 3) The pneumococcal vaccine should be indicated for all patients with RA; 4) The vaccine against varicella should be indicated for patients with RA and a negative or dubious history for that disease; 5) The HPV vaccine should be considered for adolescent and young females with RA; 6) The meningococcal vaccine is indicated for patients with RA only in the presence of asplenia or complement deficiency; 7) Asplenic adults with RA should be immunized against Haemophilus influenzae type B; 8) An additional BCG vaccine is not indicated for patients diagnosed with RA; 9) Hepatitis B vaccine is indicated for patients with RA who are negative for antibodies against HBsAg; the combined hepatitis A and B vaccine should be considered; 10) Patients with RA and at high risk for tetanus, who received rituximab in the preceding 24 weeks, should undergo passive immunization with tetanus immunoglobulin in case of exposure; 11) The YF vaccine is contraindicated to patients with RA on immunosuppressive drugs; 12) The above described recommendations should be reviewed over the course of RA.

13 Guideline EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. 2013

Colebatch, Alexandra N / Edwards, Christopher John / Østergaard, Mikkel / van der Heijde, Désirée / Balint, Peter V / D'Agostino, Maria-Antonietta / Forslind, Kristina / Grassi, Walter / Haavardsholm, Espen A / Haugeberg, Glenn / Jurik, Anne-Grethe / Landewé, Robert B M / Naredo, Esperanza / O'Connor, Philip J / Ostendorf, Ben / Potocki, Kristina / Schmidt, Wolfgang A / Smolen, Josef S / Sokolovic, Sekib / Watt, Iain / Conaghan, Philip G. ·Department of Rheumatology, University Hospital Southampton, Southampton, UK. · ·Ann Rheum Dis · Pubmed #23520036.

ABSTRACT: OBJECTIVE: To develop evidence-based recommendations on the use of imaging of the joints in the clinical management of rheumatoid arthritis (RA). METHODS: The task force comprised an expert group of rheumatologists, radiologists, methodologists and experienced rheumatology practitioners from 13 countries. Thirteen key questions on the role of imaging in RA were generated using a process of discussion and consensus. Imaging modalities included were conventional radiography, ultrasound, MRI, CT, dual-emission x-ray absorptiometry, digital x-ray radiogrammetry, scintigraphy and positron emission tomography. Research evidence was searched systematically for each question using MEDLINE, EMBASE and Cochrane CENTRAL. The experts used the evidence obtained from the relevant studies to develop a set of 10 recommendations. The strength of recommendation was assessed using a visual analogue scale. RESULTS: A total of 6888 references was identified from the search process, from which 199 studies were included in the systematic review. Ten recommendations were produced encompassing the role of imaging in making a diagnosis of RA, detecting inflammation and damage, predicting outcome and response to treatment, monitoring disease activity, progression and remission. The strength of recommendation for each proposition varied according to both the research evidence and expert opinion. CONCLUSIONS: Ten key recommendations for the role of imaging in the management of RA were developed using research-based evidence and expert opinion.

14 Guideline Abatacept use in rheumatoid arthritis: evidence review and recommendations. 2013

Martín Mola, Emilio / Balsa, Alejandro / Martínez Taboada, Víctor / Sanmartí, Raimon / Marenco, José Luis / Navarro Sarabia, Federico / Gómez-Reino, Juan / Alvaro-Gracia, José María / Román Ivorra, José Andrés / Lojo, Leticia / Plasencia, Chamaida / Carmona, Loreto / Anonymous360740. ·Servicio de Reumatología, Hospital Universitario La Paz, IdiPAZ, Madrid, España. emartinmola.hulp@salud.madrid.org · ·Reumatol Clin · Pubmed #22766432.

ABSTRACT: OBJECTIVE: To review the clinical evidence on abatacept and to formulate recommendations in order to clear up points related to its use in rheumatology. METHOD: An expert panel of rheumatologists objectively summarized the evidence on the mechanism of action, practicalities, effectiveness and safety of abatacept, and formulated recommendations following a literature review. The level of evidence and degree of recommendation was established. RESULTS: The document presents 21 statements focused on evidence or recommendations on abatacept (14 evidence summaries and 9 recommendations). The level of evidence was 2b or higher according to the Oxford Centre for Evidence-Based Medicine scale on 14 occasions. The degree of the recommendation was A in two recommendations, C in one, and D in the rest. It was considered important to make recommendations on aspects with lower levels of evidence. CONCLUSIONS: This is a practical document to supplement the summary of product characteristics.

15 Guideline [German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. 2012

Krüger, K / Wollenhaupt, J / Albrecht, K / Alten, R / Backhaus, M / Baerwald, C / Bolten, W / Braun, J / Burkhardt, H / Burmester, G / Gaubitz, M / Gause, A / Gromnica-Ihle, E / Kellner, H / Kuipers, J / Krause, A / Lorenz, H-M / Manger, B / Nüßlein, H / Pott, H-G / Rubbert-Roth, A / Schneider, M / Specker, C / Schulze-Koops, H / Tony, H-P / Wassenberg, S / Müller-Ladner, U / Anonymous5260725. ·Praxiszentrum Rheumatologie, St. Bonifatius Str. 5, 81541, München, Deutschland. Klaus.Krueger@med.uni-muenchen.de · ·Z Rheumatol · Pubmed #22930110.

ABSTRACT: Following the EULAR recommendations published in 2010 German guidelines for the medical treatment of rheumatoid arthritis were developed based on an update of the systematic literature search and expert consensus. Methotrexate is the standard treatment option at the time of diagnosis, preferably in combination with low dose glucocorticoids. Combined disease-modifying antirheumatic drugs (DMARD) therapy should be considered in patients not responding within 12 weeks. Treatment with biologicals should be initiated in patients with persistent high activity no later than 6 months after conventional treatment and in exceptional situations (e.g. early destruction or unfavorable prognosis) even earlier. If treatment with biologicals remains ineffective, changing to another biological is recommended after 3-6 months. In cases of long-standing remission a controlled reduction of medical treatment can be considered.

16 Guideline Current considerations for the management of musculoskeletal pain in Asian countries: a special focus on cyclooxygenase-2 inhibitors and non-steroid anti-inflammation drugs. 2012

Pongparadee, Chaudakshetrin / Penserga, Ester / Lee, David Jeng-Shiang / Chen, Shun-le / Gill, Ranjit Singh / Hamid, Abdulbar / Kumthornthip, Witsanu / Liu, Yi / Meliala, Lucus / Misbach, H Jusuf / Tan, Kian Hian / Yeap, Swan Sim / Yeo, Sow Nam / Lin, Hsiao Yi. ·Department of Anaesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. · ·Int J Rheum Dis · Pubmed #22898213.

ABSTRACT: Chronic pain is a complex problem that eludes precise definition and can be clinically difficult to diagnose and challenging to treat. In the Asia-Pacific region, prevalence estimates that chronic pain ranges from 12% to 45% of the population, with musculoskeletal, rheumatic or osteoarthritis pain making up the majority of the disease burden. Implementation of current management guidelines into routine clinical practice has been challenging and as a result, patients with musculoskeletal pain are often poorly managed. For these reasons, a multidisciplinary Chronic Pain Advisory Board of leading physicians from various Asian countries was convened to explore ways to improve treatment and compliance, especially among patients with osteoarthritis and rheumatoid arthritis. We have identified a number of unmet therapeutic needs and prioritized initiatives with the potential to contribute toward a more integrated approach to chronic pain management. Key priorities included using evidence-based interventions as recommended by current guidelines, particularly those aspects pertinent to addressing treatment priorities in Asia (e.g., patient compliance), and the incorporation of cyclooxygenase-2 inhibitors and non-steroid anti-inflammation drugs into the management algorithms for osteoarthritis and rheumatoid arthritis. Treatment must be individualized for each patient based on efficacy, side-effect profile and drug accessibility. Further studies are required to examine head-to-head comparisons among analgesics, combinations of analgesics and long-term efficacy outcomes. Our increasing understanding of the problem combined with the promise of new therapy options offers hope for improved management of musculoskeletal pain in Asian countries.

17 Guideline 2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis. 2012

Pereira, Ivânio Alves / Mota, Licia Maria Henrique da / Cruz, Boris Afonso / Brenol, Claiton Viegas / Fronza, Lucila Stange Rezende / Bertolo, Manoel Barros / Freitas, Max Victor Carioca de / Silva, Nilzio Antônio da / Louzada-Junior, Paulo / Giorgi, Rina Dalva Neubarth / Lima, Rodrigo Aires Corrêa / Pinheiro, Geraldo da Rocha Castelar / Anonymous4140724. ·Universidade do Sul de Santa Catarina, Florianópolis, SC, Brazil. ivanioreumato@gmail.com · ·Rev Bras Reumatol · Pubmed #22885417.

ABSTRACT: OBJECTIVE: To elaborate recommendations of the Rheumatoid Arthritis Committee of the Brazilian Society of Rheumatology (SBR) to manage comorbidities in rheumatoid arthritis (RA). METHODS: To review the literature and the opinions of the SBR RA Committee experts. RECOMMENDATIONS: 1) Early diagnosis and proper treatment of comorbidities are recommended; 2) The specific treatment of RA should be adapted to the presence of comorbidities; 3) Angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers are preferred to treat systemic arterial hypertension; 4) In patients diagnosed with rheumatoid arthritis and diabetes mellitus, the continuous use of a high cumulative dose of corticoids should be avoided; 5) Statins should be used to maintain LDL cholesterol levels under 100 mg/dL and the atherosclerotic index lower than 3.5 in patients with RA who have other comorbidities; 6) Metabolic syndrome should be treated; 7) Performing non-invasive tests to investigate subclinical atherosclerosis is recommended; 8) Greater surveillance for the early diagnosis of occult malignancy is recommended; 9) Preventive measures of venous thrombosis are suggested; 10) Bone densitometry is recommended in RA patients over the age of 50 years and in younger patients on corticoid therapy at a dose greater than 7.5 mg for over three months; 11) Patients with RA and osteoporosis should be instructed to avoid falls, to increase their dietary calcium intake and sun exposure, and to exercise; 12) Calcium and vitamin D supplementation is suggested. Bisphosphonates are suggested for patients with T score < -2.5 on bone densitometry; 13) A multidisciplinary team, with the active participation of a rheumatologist, is recommended to treat comorbidities.

18 Guideline My treatment approach to rheumatoid arthritis. 2012

Davis, John M / Matteson, Eric L / Anonymous3230721 / Anonymous3240721. ·Division of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA. davis.john4@mayo.edu · ·Mayo Clin Proc · Pubmed #22766086.

ABSTRACT: The past decade has brought important advances in the understanding of rheumatoid arthritis and its management and treatment. New classification criteria for rheumatoid arthritis, better definitions of treatment outcome and remission, and the introduction of biologic response-modifying drugs designed to inhibit the inflammatory process have greatly altered the approach to managing this disease. More aggressive management of rheumatoid arthritis early after diagnosis and throughout the course of the disease has resulted in improvement in patient functioning and quality of life, reduction in comorbid conditions, and enhanced survival.

19 Guideline Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. 2012

Bombardier, Claire / Hazlewood, Glen S / Akhavan, Pooneh / Schieir, Orit / Dooley, Anne / Haraoui, Boulos / Khraishi, Majed / Leclercq, Sharon A / Légaré, Jean / Mosher, Dianne P / Pencharz, James / Pope, Janet E / Thomson, John / Thorne, Carter / Zummer, Michel / Gardam, Michael A / Askling, Johan / Bykerk, Vivian / Anonymous5970723. ·The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, Canada. claire.bombardier@utoronto.ca · ·J Rheumatol · Pubmed #22707613.

ABSTRACT: OBJECTIVE: The Canadian Rheumatology Association (CRA) has developed recommendations for the pharmacological management of rheumatoid arthritis (RA) with traditional and biologic disease-modifying antirheumatic drugs (DMARD) in 2 parts. Part II, focusing on specific safety aspects of treatment with traditional and biologic DMARD in patients with RA, is reported here. METHODS: Key questions were identified a priori based on results of a national needs-assessment survey. A systematic review of all clinical practice guidelines and consensus statements regarding treatment with traditional and biologic DMARD in patients with RA published between January 2000 and June 2010 was performed in Medline, Embase, and CINAHL databases, and was supplemented with a "grey literature" search including relevant public health guidelines. Systematic reviews of postmarketing surveillance and RA registry studies were performed to update included guideline literature reviews as appropriate. Guideline quality was independently assessed by 2 reviewers. Guideline characteristics, recommendations, and supporting evidence from observational studies and randomized trials were synthesized into evidence tables. The working group voted on recommendations using a modified Delphi technique. RESULTS: Thirteen recommendations addressing perioperative care, screening for latent tuberculosis infection prior to the initiation of biologic DMARD, optimal vaccination practices, and treatment of RA patients with active or a history of malignancy were developed for rheumatologists, other primary prescribers of RA drug therapies, and RA patients. CONCLUSION: These recommendations were developed based on a synthesis of international RA and public health guidelines, supporting evidence, and expert consensus in the context of the Canadian health system. They are intended to help promote best practices and improve healthcare delivery for persons with RA.

20 Guideline 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis. 2012

da Mota, Licia Maria Henrique / Cruz, Boris Afonso / Brenol, Claiton Viegas / Pereira, Ivanio Alves / Rezende-Fronza, Lucila Stange / Bertolo, Manoel Barros / de Freitas, Max Victor Carioca / da Silva, Nilzio Antonio / Louzada-Júnior, Paulo / Giorgi, Rina Dalva Neubarth / Lima, Rodrigo Aires Corrêa / da Rocha Castelar Pinheiro, Geraldo / Anonymous150714. ·Programa de Pós-graduação em Ciências Médicas, Faculdade de Medicina, Universidade de Brasília. · ·Rev Bras Reumatol · Pubmed #22460407.

ABSTRACT: OBJECTIVE: To elaborate recommendations for the treatment of rheumatoid arthritis in Brazil. METHOD: Literature review with articles' selection based on evidence and the expert opinion of the Rheumatoid Arthritis Committee of the Brazilian Society of Rheumatology. RESULTS AND CONCLUSIONS: 1) The therapeutic decision should be shared with the patient; 2) immediately after the diagnosis, a disease-modifying antirheumatic drug (DMARD) should be prescribed, and the treatment adjusted to achieve remission; 3) treatment should be conducted by a rheumatologist; 4) the initial treatment includes synthetic DMARDs; 5) methotrexate is the drug of choice; 6) patients who fail to respond after two schedules of synthetic DMARDs should be assessed for the use of biologic DMARDs; 7) exceptionally, biologic DMARDs can be considered earlier; 8) anti-TNF agents are preferentially recommended as the initial biologic therapy; 9) after therapeutic failure of a first biologic DMARD, other biologics can be used; 10) cyclophosphamide and azathioprine can be used in severe extra-articular manifestations; 11) oral corticoid is recommended at low doses and for short periods of time; 12) non-steroidal anti-inflammatory drugs should always be prescribed in association with a DMARD; 13) clinical assessments should be performed on a monthly basis at the beginning of treatment; 14) physical therapy, rehabilitation, and occupational therapy are indicated; 15) surgical treatment is recommended to correct sequelae; 16) alternative therapy does not replace traditional therapy; 17) family planning is recommended; 18) the active search and management of comorbidities are recommended; 19) the patient's vaccination status should be recorded and updated; 20) endemic-epidemic transmissible diseases should be investigated and treated.

21 Guideline Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. 2012

Bykerk, Vivian P / Akhavan, Pooneh / Hazlewood, Glen S / Schieir, Orit / Dooley, Anne / Haraoui, Boulos / Khraishi, Majed / Leclercq, Sharon A / Légaré, Jean / Mosher, Diane P / Pencharz, James / Pope, Janet E / Thomson, John / Thorne, Carter / Zummer, Michel / Bombardier, Claire / Anonymous5940723. ·Mount Sinai Hospital, The Rebecca McDonald Centre for Arthritis and Autoimmune Disease, Toronto, Canada. vbykerk@mtsinai.on.ca · ·J Rheumatol · Pubmed #21921096.

ABSTRACT: OBJECTIVE: The Canadian Rheumatology Association (CRA) has developed recommendations for the pharmacological management of rheumatoid arthritis (RA) with traditional and biologic disease-modifying antirheumatic drugs (DMARD) in 2 parts. Part 1 is reported here. METHODS: The CRA Therapeutics Committee assembled a national working group of RA clinical experts, researchers, patient consumers, and a general practitioner. Treatment questions were developed a priori based on results of a national needs assessment survey. A systematic review of all clinical practice guidelines and consensus statements regarding treatment with traditional and biologic DMARD in patients with RA published between January 2000 and June 2010 was performed in Medline, Embase, and CINAHL databases, and the grey literature. Guideline quality was assessed by 2 independent reviewers, and guideline characteristics, recommendations, and supporting evidence from observational studies and randomized controlled trials were synthesized into evidence tables. The full working group reviewed the evidence tables and developed recommendations using a modified Delphi technique. RESULTS: Five overarching principles and 26 recommendations addressing general RA management strategies and treatment with glucocorticoids and traditional and biologic DMARD were developed for rheumatologists, other primary prescribers of RA drug therapies, and patients with RA. CONCLUSION: These recommendations were developed based on a synthesis of international guidelines, supporting evidence, and expert consensus considering the Canadian healthcare context with the intention of promoting best practices and improving healthcare delivery for persons with RA.

22 Guideline [Practical guide for the use of biological agents in rheumatoid arthritis - December 2011 update]. 2011

Mourão, Ana Filipa / Fonseca, João Eurico / Canhão, Helena / Santos, Maria José / Bernardo, Alexandra / Cordeiro, Ana / Cravo, Ana Rita / Ribeiro, Ana / Teixeira, Ana / Barcelos, Anabela / Malcata, Armando / Faustino, Augusto / Duarte, Cátia / Ribeiro, Célia / Nour, Dolores / Araújo, Domingos / Sousa, Elsa / Mariz, Eva / Ramos, Filipa / Vinagre, Filipe / Ventura, Francisco Simões / Sequeira, Graça / Santos, Helena / Branco, Jaime Cunha / Gomes, J A / Silva, J A / Ramos, João / Santo, Jorge Espírito / Costa, José António / Silva, J A / Ribeiro, José Saraiva / Inês, Luís / Miranda, Luís / Sampaio, Luzia / Costa, Maria Lúcia / Rodrigues, Mário / Afonso, Maria Carmo / Cunha, Maria Inês / Saavedra, Maria João / Queiroz, Mário Viana / Couto, Maura / Bernardes, Miguel / Bogas, Mónica / Pinto, Patrícia / Valente, Paula / Coelho, Paulo / Abreu, Pedro / Cortes, Sara / Pimenta, Sofia / Ramiro, Sofia / Figueira, Ricardo / Nóvoa, Teresa / Anonymous5080705. ·Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Portugal. filipamourao@yahoo.com · ·Acta Reumatol Port · Pubmed #22472930.

ABSTRACT: The authors review the practical aspects of biological therapy use for rheumatoid arthritis patients, commenting safety issues before and after treatment initiation and the best treatment strategies to optimize efficacy.

23 Guideline Portuguese guidelines for the use of biological agents in rheumatoid arthritis - October 2011 update. 2011

Fonseca, João Eurico / Bernardes, Miguel / Canhão, Helena / Santos, Maria José / Quintal, Alberto / Malcata, Armando / Neto, Adriano / Cordeiro, Ana / Rodrigues, Ana / Mourão, Ana Filipa / Ribeiro, Ana Sofia / Cravo, Ana Rita / Barcelos, Anabela / Cardoso, Anabela / Vilar, António / Braña, Arecili / Faustino, Augusto / Silva, Candida / Duarte, Cátia / Araújo, Domingos / Nour, Dolores / Sousa, Elsa / Simões, Eugénia / Godinho, Fátima / Brandão, Filipe / Ventura, Francisco / Sequeira, Graça / Figueiredo, Guilherme / Cunha, Inês / Matos, J Alves / Branco, Jaime / Ramos, João / Costa, José António / Gomes, José António / Pinto, José / Silva, José Canas / Silva, J A / Patto, José Vaz / Costa, Lúcia / Miranda, Luís Cunha / Inês, Luís / Santos, Luís Maurício / Cruz, Margarida / Salvador, Maria João / Ferreira, Maria Júlia / Rial, Maria / Queiroz, Mário Viana / Bogas, Mónica / Araújo, Paula / Reis, Paulo / Abreu, Pedro / Machado, Pedro / Pinto, Patrícia / André, Rui / Melo, Rui / Garcês, Sandra / Cortes, Sara / Alcino, Sérgio / Ramiro, Sofia / Capela, Susana / Anonymous5070705. ·Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Portugal. jefonseca@netcabo.pt · ·Acta Reumatol Port · Pubmed #22472929.

ABSTRACT: The authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of Rheumatoid Arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the contraindications and procedures in the case of nonresponders. Biological treatment (with a tumour necrosis factor antagonist, abatacept or tocilizumab) should be considered in RA patients with a disease activity score 28 (DAS 28) equal to or greater than 3.2 despite treatment with at least 20mg-weekly-dose of methotrexate (MTX) for at least 3 months or, if such treatment is not possible, after 3 months of other conventional disease modifying drug or combination therapy. A DAS 28 score between 2.6 and 3.2 with a significant functional or radiological deterioration under treatment with conventional regimens could also constitute an indication for biological treatment. The treatment goal should be remission or, if that is not achievable, at least a low disease activity, defined by a DAS28 lower than 3.2, without significative functional or radiological worsening. The response criteria, at the end of the first 3 months of treatment, are a decrease of at least 0.6 in the DAS28 score. After 6 months of treatment res­ponse criteria is defined as a decrease greater than 1.2 in the DAS28 score. Non-responders, in accordance to the Rheumatologist’s clinical opinion, should try a switch to another biological agent (tumour necrosis factor antagonist, abatacept, rituximab or tocilizumab).

24 Guideline Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. 2011

Favalli, Ennio G / Caporali, Roberto / Sinigaglia, Luigi / Pipitone, Nicolo' / Miniati, Irene / Montecucco, Carlomaurizio / Matucci-Cerinic, Marco / Anonymous5120696. ·Dipartimento di Reumatologia, Struttura Complessa di Reumatologia DH, Istituto ortopedico G. Pini, Milano, Italy. ennio.favalli@fastwebnet.it · ·Clin Exp Rheumatol · Pubmed #21906424.

ABSTRACT: Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific recommendations in order to assist rheumatologists in prescribing these drugs. The Italian Society for Rheumatology (Società Italiana di Reumatologia, SIR) decided to update its recommendations, and, to this end, a systematic literature review was performed and the evidence derived from it was discussed and summarized as expert opinions. Levels of evidence and strength of recommendations were reported. The recommendations reported refer to the safety of biologic agents and are intended to help prescribing rheumatologists to optimise the use of biologic agents in patients with RA seen in everyday practice; they are not to be considered as a regulatory rule.

25 Guideline Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. 2011

Caporali, Roberto / Conti, Fabrizio / Alivernini, Stefano / Atzeni, Fabiola / Seriolo, Bruno / Cutolo, Maurizio / Valesini, Guido / Ferraccioli, Gianfranco / Sarzi-Puttini, Piercarlo / Salvarani, Carlo / Guiducci, Serena / Zampogna, Giuseppe / Gremese, Elisa / Pipitone, Nicolo' / Scrivo, Rossana / Bugatti, Serena / Montecucco, Carlomaurizio / Matucci-Cerinic, Marco / Anonymous5110696. ·Division of di Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy. caporali@smatteo.pv.it · ·Clin Exp Rheumatol · Pubmed #21906423.

ABSTRACT: Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific recommendations in order to assist rheumatologists in prescribing these drugs. The Italian Society for Rheumatology (Società Italiana di Reumatologia, SIR) decided to update its recommendations and, to this end, a systematic literature review was carried out and the evidence derived from it was discussed and summarised as expert opinions. Levels of evidence, strength of recommendations and levels of agreement were reported. The recommendations reported are intended to help prescribing rheumatologists to optimise the use of biologic agents in patients with RA seen in everyday practice; they are not to be considered as a regulatory rule.

Next